News

Immunicum Develops a Cancer Vaccine that Almost Doubled the Patients’


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Immunicum Develops a Cancer Vaccine that Almost Doubled the Patients’ Survival


Date: 05/08/2015


Gothenburg-based Immunicum AB, just announced that seven patients with metastatic renal cell cancer, which received the cancer vaccine INTUVAX, have shown continued improvement in survival. These results strengthen the hopes to someday find an effective cure to cancer.

The immuno-oncology field is becoming literally crowded with innovative companies trying to find the best approach to definitely cure patients from cancer. Among these approaches, therapeutic vaccines are showing a great potential as they can theoretically lead to the complete remission of the disease and even immunize the patients. In this field, Immunicum is showing encouraging results.

The company reported today updated survival data from its phase I/II study in patients with metastatic renal cancer treated with the cancer vaccine INTUVAX. Seven of the 11 patients evaluable for efficacy are still alive. Median overall survival for the entire patient group is currently at 26.5 months versus expected 15.2 months for patients treated with current available therapies.

For more click here

Source: Labiotech

© Catalyst Innovation Portal 2019